Quantum Cyber NV Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $537.1K-39.9% YoYTTM through 30 Jun 2026
Net Income -$23.8MTTM through 30 Jun 2026
Free Cash Flow -$14.4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | -4,490.1% |
| Net Margin | -4,436.3% |
Returns
-117.0%ROE
-102.0%ROA
Balance Sheet Health
Debt / Equity0.05x
Current Ratio5.56x
Net Debt-$12.4Mnet cash position
Cash & Equivalents$13.4M
Quality Metrics
Altman Z-Score12.23
Piotroski F-Score3 / 9
FCF Margin-2,679.3%
Multi-Year Trend
RevenueFY2025: $537.1K
Diluted EPS-$1.61TTMFY2025: $-2.70
Dividend
No dividend
Capital Allocation
Capex Intensity25.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Genetic Diagnostic Testing | View detailsIn February 2026, the Board made the decision to close the Company's colorectal cancer line of business to focus on the pancreatic screening line of business, marketing the colorectal assets for sale. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.